

ROITT'S

# ESSENTIAL IMMUNOLOGY

Ivan Roitt

NINTH EDITION



*b*

Blackwell  
Science

**DOCKET**  
**A L A R M**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

© 1971, 1974, 1977, 1980, 1984, 1988,  
1991, 1994, 1997 by Blackwell Science Ltd  
Editorial Offices:  
Osney Mead, Oxford OX2 0EL  
25 John Street, London WC1N 2BL  
23 Ainslie Place, Edinburgh EH3 6AJ  
350 Main Street, Malden  
MA 02148 5018, USA  
54 University Street, Carlton  
Victoria 3053, Australia

Other Editorial Offices:

Blackwell Wissenschafts-Verlag GmbH  
Kurfürstendamm 57  
10707 Berlin, Germany  
Zehetnergasse 6  
A-1140 Wien  
Austria

All rights reserved. No part of  
this publication may be reproduced,  
stored in a retrieval system, or  
transmitted, in any form or by any  
means, electronic, mechanical,  
photocopying, recording or otherwise,  
except as permitted by the UK  
Copyright, Designs and Patents Act  
1988, without the prior permission  
of the copyright owner.

Set by Excel Typesetters Co., Hong Kong  
Printed and bound in Italy  
by Rotolito Lombarda S.p.A., Milan

The Blackwell Science logo is a  
trade mark of Blackwell Science Ltd,  
registered at the United Kingdom  
Trade Marks Registry

First published 1971  
Reprinted 1972 (twice), 1973 (twice)  
Second edition 1974, Reprinted 1975  
Third edition 1977, Reprinted 1978, 1979  
Fourth edition 1980, Reprinted 1982, 1983  
Fifth edition 1984  
Sixth edition 1988, Reprinted 1988  
Reprinted with corrections 1989  
Seventh edition 1991  
Eighth edition 1994, Reprinted 1996  
Ninth edition 1997  
Spanish editions 1972, 1975, 1978, 1982,  
1988, 1989, 1993  
Italian editions 1973, 1975, 1979, 1986,  
1988, 1990, 1993, 1995  
Portuguese editions 1973, 1979, 1983  
French editions 1975, 1979, 1990  
Dutch editions 1975, 1978, 1982  
Japanese editions 1976, 1978, 1982, 1986, 1988  
German editions 1977, 1984, 1988, 1993  
Polish edition 1977  
Greek editions 1978, 1989, 1992  
Turkish edition 1979  
Slovak edition 1981  
Indonesian editions 1985, 1991  
Russian edition 1988  
Korean edition 1991  
ELBS editions 1977, 1982, 1988, Reprinted 1991  
Chinese (Taiwan) editions 1991, 1994

DISTRIBUTORS

Marston Book Services Ltd  
PO Box 269  
Abingdon  
Oxon OX14 4YN  
(Orders: Tel: 01235 465500  
Fax: 01235 465555)

USA

Blackwell Science, Inc.  
Commerce Place  
350 Main Street  
Malden, MA 02148 5018  
(Orders: Tel: 800 759 6102  
617 388 8250  
Fax: 617 388 8255)

Canada

Copp Clark Professional  
200 Adelaide St West, 3rd Floor  
Toronto, Ontario M5H 1W7  
(Orders: Tel: 416 597-1616  
800 815-9417  
Fax: 416 597-1617)

Australia

Blackwell Science Pty Ltd  
54 University Street  
Carlton, Victoria 3053  
(Orders: Tel: 3 9347 0300  
Fax: 3 9347 5001)

Catalogue records for this title  
are available from the British Library  
and the Library of Congress

ISBN 0-86542-729-1

# CONTENTS

<b>PREFACE</b> . . . . .	xiii
<b>ACKNOWLEDGEMENTS</b> . . . . .	xiv
<b>ABBREVIATIONS</b> . . . . .	xv
<b>USER GUIDE</b> . . . . .	xix

## PART 1 • THE BASIS OF IMMUNOLOGY

### 1 • Innate immunity, 3

<b>EXTERNAL BARRIERS AGAINST INFECTION</b> . . . . .	3
<b>PHAGOCYtic CELLS KILL MICROORGANISMS</b> . . . . .	6
Polymorphs and macrophages are dedicated 'professional' phagocytes . . . . .	6
The polymorphonuclear neutrophil . . . . .	6
The macrophage . . . . .	6
Microbes are engulfed by phagocytosis . . . . .	6
There is an array of killing mechanisms . . . . .	8
Killing by reactive oxygen intermediates . . . . .	8
Killing by reactive nitrogen intermediates . . . . .	9
Killing by preformed antimicrobials . . . . .	10
<b>COMPLEMENT FACILITATES PHAGOCYtOSIS</b> . . . . .	11
Complement and its activation . . . . .	11
C3 undergoes slow spontaneous cleavage . . . . .	11
C3b levels are normally tightly controlled . . . . .	11
C3 convertase is stabilized on microbial surfaces . . . . .	11
The post-C3 pathway generates a membrane attack complex . . . . .	12
Complement has a range of defensive biological functions . . . . .	12
1 C3b adheres to complement receptors . . . . .	12
2 Biologically active fragments are released . . . . .	12
3 The terminal complex can induce membrane lesions . . . . .	14
<b>COMPLEMENT CAN MEDIATE AN ACUTE INFLAMMATORY REACTION</b> . . . . .	14
The mast cell plays a central role . . . . .	14
Macrophages can also do it . . . . .	15
<b>HUMORAL MECHANISMS PROVIDE A SECOND DEFENSIVE STRATEGY</b> . . . . .	16
Acute phase proteins increase in response to infection . . . . .	16
Interferons inhibit viral replication . . . . .	18
<b>EXTRACELLULAR KILLING</b> . . . . .	18
Natural killer (NK) cells . . . . .	18

Target cells are told to commit suicide . . . . .	19
Eosinophils . . . . .	20
<b>SUMMARY</b> . . . . .	20

### 2 • Specific acquired immunity, 22

<b>THE NEED FOR SPECIFIC IMMUNE MECHANISMS</b> . . . . .	22
<b>ANTIBODY – THE SPECIFIC ADAPTOR</b> . . . . .	22
Antibody initiates a new complement pathway ('classical') . . . . .	23
Complexed antibody activates phagocytic cells . . . . .	25
<b>CELLULAR BASIS OF ANTIBODY PRODUCTION</b> . . . . .	25
Antibodies are made by lymphocytes . . . . .	25
Antigen selects the lymphocytes which make antibody . . . . .	26
The need for clonal expansion means humoral immunity must be acquired . . . . .	26
<b>ACQUIRED MEMORY</b> . . . . .	28
Secondary antibody responses are better . . . . .	28
<b>ACQUIRED IMMUNITY HAS ANTIGEN SPECIFICITY</b> . . . . .	30
Discrimination between different antigens . . . . .	30
Discrimination between self and nonself . . . . .	32
<b>VACCINATION DEPENDS ON ACQUIRED MEMORY</b> . . . . .	32
<b>CELL-MEDIATED IMMUNITY PROTECTS AGAINST INTRACELLULAR ORGANISMS</b> . . . . .	33
Cytokine-producing T-cells help macrophages to kill intracellular parasites . . . . .	33
Virally infected cells can be killed by cytotoxic T-cells and ADCC . . . . .	33
<b>IMMUNOPATHOLOGY</b> . . . . .	35
<b>SUMMARY</b> . . . . .	35
<b>FURTHER READING</b> . . . . .	37
General reading . . . . .	37
Reference work . . . . .	37
Historical . . . . .	38
In-depth series for the advanced reader . . . . .	38
Current information . . . . .	38
Multiple choice questions . . . . .	38
Electronic publications (linked to 'Rollit's Essential Immunology') . . . . .	39
Major journals . . . . .	39

**PART 2 · THE RECOGNITION OF ANTIGEN****3 · Antibodies, 43**

<b>THE BASIC STRUCTURE IS A FOUR-PEPTIDE UNIT</b> . . . . .	43
<b>AMINO ACID SEQUENCES REVEAL VARIATIONS IN IMMUNOGLOBULIN STRUCTURE</b> . . . . .	45
<b>IMMUNOGLOBULIN GENES</b> . . . . .	45
Immunoglobulins are encoded by multiple gene segments . . . . .	45
A special mechanism effects VDJ recombination . . . . .	46
<b>STRUCTURAL VARIANTS OF THE BASIC IMMUNOGLOBULIN MOLECULE</b> . . . . .	47
Isotypes . . . . .	47
Allotypes . . . . .	47
Idiotypes . . . . .	50
<b>IMMUNOGLOBULINS ARE FOLDED INTO GLOBULAR DOMAINS WHICH SUBSERVE DIFFERENT FUNCTIONS</b> . . . . .	50
Immunoglobulin domains have a characteristic structure . . . . .	50
The variable domain binds antigen . . . . .	51
Constant region domains determine secondary biological function . . . . .	51
<b>IMMUNOGLOBULIN CLASSES AND SUBCLASSES</b> . . . . .	51
Immunoglobulin G has major but varied roles in extracellular defenses . . . . .	53
Activation of the classical complement pathway . . . . .	53
The diversity of Fcγ receptors . . . . .	54
Nonprecipitating 'univalent' antibodies . . . . .	57
Immunoglobulin A guards the mucosal surfaces . . . . .	57
Immunoglobulin M provides a defense against bacteremia . . . . .	58
Immunoglobulin D is a cell surface receptor . . . . .	59
Immunoglobulin E triggers inflammatory reactions . . . . .	59
Immunoglobulins are further subdivided into subclasses . . . . .	60
<b>SUMMARY</b> . . . . .	61
<b>FURTHER READING</b> . . . . .	62

**4 · Membrane receptors for antigen, 63**

<b>THE B-CELL SURFACE RECEPTOR FOR ANTIGEN</b> . . . . .	63
The B-cell inserts a transmembrane Immunoglobulin into its surface . . . . .	63
The surface Immunoglobulin is complexed with associated membrane proteins . . . . .	64
<b>THE T-CELL SURFACE RECEPTOR FOR ANTIGEN</b> . . . . .	65
The receptor for antigen is a transmembrane heterodimer . . . . .	65
There are two classes of T-cell receptors . . . . .	65
The encoding of T-cell receptors is similar to that of Immunoglobulins . . . . .	66
The CD3 complex is an integral part of the T-cell receptor . . . . .	67
<b>THE GENERATION OF DIVERSITY FOR ANTIGEN RECOGNITION</b> . . . . .	68
Intrachain amplification of diversity . . . . .	69
Random VDJ combination increases diversity geometrically . . . . .	69
Playing with the junctions . . . . .	69
Interchain amplification . . . . .	70
Somatic hypermutation . . . . .	70
<b>THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC)</b> . . . . .	71
Class I and class II molecules are membrane-bound heterodimers . . . . .	71
MHC class I . . . . .	71
MHC class II . . . . .	71

Complement genes contribute to the remaining class III region of the MHC . . . . .	72
Gene map of the MHC . . . . .	72
The genes of the MHC display remarkable polymorphism . . . . .	75
Nomenclature . . . . .	75
Inheritance of the MHC . . . . .	77
The tissue distribution of MHC molecules . . . . .	77
MHC functions . . . . .	77
<b>SUMMARY</b> . . . . .	78
<b>FURTHER READING</b> . . . . .	79

**5 · The primary interaction with antigen, 80**

<b>WHAT IS AN ANTIGEN?</b> . . . . .	80
Of epitopes and antigen determinants . . . . .	81
Identification of B-cell epitopes . . . . .	81
<b>ANTIGENS AND ANTIBODIES INTERACT BY SPATIAL COMPLEMENTARITY NOT BY COVALENT BONDING</b> . . . . .	83
Variation in hapten structure shows importance of shape . . . . .	83
Spatial complementarity of epitope and paratope can be demonstrated . . . . .	83
Antigen-antibody bonds are readily reversible . . . . .	84
<b>THE FORCES BINDING ANTIGEN TO ANTIBODY BECOME LARGE AS INTERMOLECULAR DISTANCES BECOME SMALL</b> . . . . .	86
1 Electrostatic . . . . .	86
2 Hydrogen bonding . . . . .	87
3 Hydrophobic . . . . .	87
4 Van der Waals . . . . .	87
<b>AFFINITY MEASURES STRENGTH OF BINDING OF ANTIGEN AND ANTIBODY</b> . . . . .	88
The avidity of antiserum for antigen — the bonus effect of multivalency . . . . .	88
<b>THE SPECIFICITY OF ANTIGEN RECOGNITION BY ANTIBODY IS NOT ABSOLUTE</b> . . . . .	90
<b>WHAT THE T-CELL SEES</b> . . . . .	91
Haplotype restriction reveals the need for MHC participation . . . . .	91
T-cells recognize a linear peptide sequence from the antigen . . . . .	91
<b>PROCESSING OF INTRACELLULAR ANTIGEN FOR PRESENTATION BY CLASS I MHC</b> . . . . .	92
<b>PROCESSING OF ANTIGEN FOR CLASS II MHC PRESENTATION FOLLOWS A DIFFERENT PATHWAY</b> . . . . .	93
<b>THE NATURE OF THE 'GROOVY' PEPTIDE</b> . . . . .	96
Binding to MHC class I . . . . .	96
Binding to MHC class II . . . . .	97
<b>THE αβ T-CELL RECEPTOR FORMS A TERNARY COMPLEX WITH MHC AND ANTIGENIC PEPTIDE</b> . . . . .	98
Topology of the ternary complex . . . . .	99
<b>T-CELLS WITH A DIFFERENT OUTLOOK</b> . . . . .	99
Non-classical class I molecules can also present antigen . . . . .	99
MHC class I-like molecules . . . . .	99
The family of CD1 non-MHC class I-like molecules can present exotic antigens . . . . .	99
γδ TCRs have some features of antibody . . . . .	100
<b>SUPERANTIGENS STIMULATE WHOLE FAMILIES OF LYMPHOCYTE RECEPTORS</b> . . . . .	100
Bacterial toxins represent one major group of T-cell superantigens . . . . .	100
Endogenous mouse mammary tumor viruses (MMTV) act as superantigens . . . . .	100
Microbes can also provide B-cell superantigens . . . . .	101

<b>THE RECOGNITION OF DIFFERENT FORMS OF ANTIGEN BY B- AND T-CELLS IS ADVANTAGEOUS TO THE HOST</b> . . . . .	101
<b>SUMMARY</b> . . . . .	102
<b>FURTHER READING</b> . . . . .	103

## PART 3 • TECHNOLOGY

### 6 • Immunochemical techniques, 107

<b>ESTIMATION OF ANTIBODY</b> . . . . .	107
Antigen-antibody interactions in solution . . . . .	107
What does serum 'antibody content' mean? . . . . .	107
The classical precipitin reaction . . . . .	109
Nonprecipitating antibodies can be detected by nephelometry . . . . .	109
Complexes formed by nonprecipitating antibodies can be precipitated . . . . .	110
Enhancement of precipitation by countercurrent immunoelectrophoresis . . . . .	110
Measurement of antibody affinity . . . . .	110
Agglutination of antigen-coated particles . . . . .	111
Immunoassay for antibody using solid-phase antigen . . . . .	112
The principle . . . . .	112
A wide variety of labels is available . . . . .	113
ELISA (enzyme-linked immunosorbent assay) . . . . .	113
Other labels . . . . .	113
Surface plasmon resonance . . . . .	114
<b>IDENTIFICATION AND MEASUREMENT OF ANTIGEN</b> . . . . .	114
Precipitation reaction can be carried out in gels . . . . .	114
Characterization of antigens by electrophoresis and immunofixation . . . . .	114
Quantification by single radial immunodiffusion (SRID) . . . . .	115
The nephelometric assay for antigen . . . . .	115
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for analysis of immunoprecipitates and immunoblotting . . . . .	118
The immunoassay of antigens . . . . .	117
Immunoassay on multiple microspots . . . . .	118
Epitope mapping . . . . .	118
T-cell epitopes . . . . .	118
B-cell epitopes . . . . .	119
<b>DETECTION OF IMMUNE COMPLEX FORMATION</b> . . . . .	120
<b>MAKING ANTIBODIES TO ORDER</b> . . . . .	120
The monoclonal antibody revolution . . . . .	120
First in rodents . . . . .	120
Catalytic antibodies . . . . .	121
Human monoclonals can be made . . . . .	123
Engineering antibodies . . . . .	124
Fields of antibodies . . . . .	125
Drugs can be based on the CDRs of minibodies . . . . .	125
<b>PURIFICATION OF ANTIGENS AND ANTIBODIES BY AFFINITY CHROMATOGRAPHY</b> . . . . .	126
<b>NEUTRALIZATION OF BIOLOGICAL ACTIVITY</b> . . . . .	127
To detect antibody . . . . .	127
Using antibody as an inhibitor . . . . .	127
<b>SUMMARY</b> . . . . .	128
<b>FURTHER READING</b> . . . . .	129

### 7 • Cellular techniques, 130

<b>ISOLATION OF LEUKOCYTE SUBPOPULATIONS</b> . . . . .	130
--	-----

Bulk techniques . . . . .	130
Separation based on physical parameters . . . . .	130
Separation exploiting biological parameters . . . . .	131
Selection by antibody coating . . . . .	131
Cell selection by the FACS . . . . .	131
Enrichment of antigen-specific populations . . . . .	131

## IMMUNOHISTOCHEMISTRY — LOCALIZATION

<b>OF ANTIGENS IN CELLS AND TISSUES</b> . . . . .	133
Immunofluorescence techniques . . . . .	133
Direct test with labeled antibody . . . . .	134
Indirect test for antibody . . . . .	134
High resolution with the confocal microscope . . . . .	135
Flow cytometry . . . . .	135
The detection and isolation of rare cells . . . . .	137
Other labeled antibody methods . . . . .	139
Localization in tissues of a gene product . . . . .	139
<b>ASSESSMENT OF FUNCTIONAL ACTIVITY</b> . . . . .	140
The activity of phagocytic cells . . . . .	140
Lymphocyte responsiveness . . . . .	140
Limiting dilution analysis . . . . .	140
Enumeration of antibody-forming cells . . . . .	140
The immunofluorescence sandwich test . . . . .	140
Plaque techniques . . . . .	141
Analysis of functional activity by cellular reconstitution . . . . .	142
Radiation chimeras . . . . .	142
Mice with severe combined immunodeficiency (SCID) . . . . .	142
Cellular interactions <i>in vitro</i> . . . . .	142
Probing function with antibodies . . . . .	143
<b>GENETIC ENGINEERING OF CELLS</b> . . . . .	144
Insertion and modification of genes in mammalian cells . . . . .	144
Introducing new genes into animals . . . . .	144
Establishing 'designer mice' bearing new genes . . . . .	144
Transgenes introduced into embryonic stem cells . . . . .	144
Gene therapy in humans . . . . .	145
<b>SUMMARY</b> . . . . .	147
<b>FURTHER READING</b> . . . . .	148

## PART 4 • THE ACQUIRED IMMUNE RESPONSE

### 8 • The anatomy of the immune response, 151

<b>THE SURFACE MARKERS OF CELLS IN THE IMMUNE SYSTEM</b> . . . . .	151
<b>THE NEED FOR ORGANIZED LYMPHOID TISSUE</b> . . . . .	151
<b>LYMPHOCYTES TRAFFIC BETWEEN LYMPHOID TISSUES</b> . . . . .	153
Lymphocytes home to their specific tissues . . . . .	153
Transmigration occurs in three stages . . . . .	153
Step 1: Tethering and rolling . . . . .	153
Step 2: $\beta_2$ Integrin activation and cell flattening . . . . .	154
Step 3: Transmigration into the tissue (diapedesis) . . . . .	154
A closer look at the interacting receptors and their ligands . . . . .	156
<b>ENCAPSULATED LYMPH NODES</b> . . . . .	156
B-cell areas . . . . .	156
T-cell areas . . . . .	157
<b>SPLEEN</b> . . . . .	158
<b>MUCOSAL-ASSOCIATED LYMPHOID TISSUE (MALT)</b> . . . . .	161
Intestinal lymphocytes . . . . .	162
<b>BONE MARROW CAN BE A MAJOR SITE OF ANTIBODY SYNTHESIS</b> . . . . .	162



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.